Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | NQO1 | P15559 | 2/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371790 | 1.00 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL29435144 | 1.00 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5953239 | 0.99 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29613355 | 0.99 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL8542307 | 0.94 | KIT (0.48) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL7640244 | 0.92 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL27118310 | 0.91 | POLB (0.46) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL24277141 | 0.90 | ALDH1A1 (0.40) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL5140974 | 0.89 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL30986316 | 0.89 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2041 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| EP-2603222-B1 | COMBINATORY CANCER TREATMENT | UNIV MONTREAL (CA) | 2018-10-17 | — | — | EP | claimed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | claimed |
| WO-2016168670-A2 | METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES | LONGEVICA THERAPEUTICS INC. (US) | 2016-10-20 | — | — | WO | claimed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130209578-A1 | Combinatory Cancer Treatment | UNIVERSITE DE MONTREAL (CA) | 2013-08-15 | — | — | US | claimed |
| EP-2603222-A1 | COMBINATORY CANCER TREATMENT | UNIVERSITE DE MONTREAL (CA) | 2013-06-19 | — | — | EP | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| WO-2012019284-A1 | COMBINATORY CANCER TREATMENT | UNIVERSITE DE MONTREAL (CA) | 2012-02-16 | — | — | WO | claimed |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20030225150-A1 | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2003-12-04 | — | — | US | claimed |
| EP-0591058-B1 | Ellipticine derivatives with antitumor activity | ADIR (FR) | 1998-06-03 | — | — | EP | claimed |
| US-5407940-A | Antitumor agents | ADIR ET COMPAGNIE (FR) | 1995-04-18 | — | — | US | claimed |
| EP-0591058-A1 | Ellipticine derivatives with antitumor activity | ADIR ET COMPAGNIE (FR) | 1994-04-06 | — | — | EP | claimed |
| JP-6211852-A | — | — | None | — | — | JP | disclosed |
| JP-H06211852-A | NOVEL ELLIPTICINE COMPOUND, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | ADIR | 1994-08-02 | — | — | JP | disclosed |
| EP-0591058-A1 | Ellipticine derivatives with antitumor activity | ADIR ET COMPAGNIE (FR) | 1994-04-06 | — | — | EP | disclosed |